ClearPoint Neuro/$CLPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ClearPoint Neuro
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Ticker
$CLPT
Sector
Primary listing
Employees
115
Headquarters
Website
ClearPoint Neuro Metrics
BasicAdvanced
$303M
-
-$0.80
0.85
-
Price and volume
Market cap
$303M
Beta
0.85
52-week high
$19.22
52-week low
$9.76
Average daily volume
321K
Financial strength
Current ratio
7.298
Quick ratio
6.191
Long term debt to equity
177.911
Total debt to equity
179.588
Profitability
EBITDA (TTM)
-21.645
Gross margin (TTM)
60.42%
Net profit margin (TTM)
-66.15%
Operating margin (TTM)
-67.42%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-24.52%
Return on equity (TTM)
-85.68%
Valuation
Price to revenue (TTM)
8.819
Price to book
15.35
Price to tangible book (TTM)
15.35
Price to free cash flow (TTM)
-25.29
Free cash flow yield (TTM)
-3.95%
Free cash flow per share (TTM)
-0.422
Growth
Revenue change (TTM)
19.68%
Earnings per share change (TTM)
13.58%
3-year revenue growth (CAGR)
20.74%
10-year revenue growth (CAGR)
25.63%
3-year earnings per share growth (CAGR)
3.24%
10-year earnings per share growth (CAGR)
-21.12%
What the Analysts think about ClearPoint Neuro
Analyst ratings (Buy, Hold, Sell) for ClearPoint Neuro stock.
Bulls say / Bears say
Delivered record Q2 2025 revenue of $9.22 million, a 17% increase from $7.86 million in Q2 2024, driven by broad-based growth across segments (Nasdaq)
Posted Q1 2025 revenue of $8.49 million, surpassing the Zacks consensus estimate by 2.85% and demonstrating sustained sales momentum early in the year (Nasdaq)
Received FDA clearance expanding the ClearPoint Prism Neuro Laser Therapy System to include 1.5 T MRI guidance, effectively doubling its addressable U.S. Neuro LITT market opportunity (Reuters)
Reported Q2 2025 net loss of $0.21 per share missed the consensus estimate of $0.20, highlighting ongoing profitability challenges (Nasdaq)
Q2 2025 revenue of $9.22 million fell 3% short of the Zacks consensus estimate, indicating underperformance relative to analyst forecasts (Nasdaq)
In Q1 2025, EPS of –$0.22 per share represented a 46.7% miss to consensus estimates, marking continued earnings surprises and volatility (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2025.
ClearPoint Neuro Financial Performance
Revenues and expenses
ClearPoint Neuro Earnings Performance
Company profitability
ClearPoint Neuro News
AllArticlesVideos
ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners
Accesswire2 weeks ago
ClearPoint Neuro Reports Second Quarter 2025 Results
Accesswire1 month ago
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio
Accesswire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ClearPoint Neuro stock?
ClearPoint Neuro (CLPT) has a market cap of $303M as of September 19, 2025.
What is the P/E ratio for ClearPoint Neuro stock?
The price to earnings (P/E) ratio for ClearPoint Neuro (CLPT) stock is 0 as of September 19, 2025.
Does ClearPoint Neuro stock pay dividends?
No, ClearPoint Neuro (CLPT) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next ClearPoint Neuro dividend payment date?
ClearPoint Neuro (CLPT) stock does not pay dividends to its shareholders.
What is the beta indicator for ClearPoint Neuro?
ClearPoint Neuro (CLPT) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.